NCT02726711 is a Phase 1 clinical trial of Trimethaphan in Multiple System Atrophy, sponsored by Vanderbilt University.

Who is sponsoring NCT02726711?

NCT02726711 is sponsored by Vanderbilt University.

What drugs are being tested in NCT02726711?

Interventions in NCT02726711: Trimethaphan, Placebo.

What condition does NCT02726711 study?

NCT02726711 studies Multiple System Atrophy, Orthostatic Hypotension, Supine Hypertension.

Is NCT02726711 still recruiting?

NCT02726711 is currently active, enrolled. Last updated 11 March 2026.

Last reviewed 2026-03-11 · How we verify

NCT02726711

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Reduction in Splanchnic Capacitance Contributes to Sympathetically Dependent Hypertension in Autonomic Aim 1 of Rare Diseases Clinical Research Network (RDCRN) Project 2

Active, enrolled Phase 1 Last updated 11 March 2026

What this trial tests

Phase 1 trial testing Trimethaphan in Multiple System Atrophy in 2 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

1 April 2016

Primary endpoint
1 December 2026

1 December 2026

Quick facts

Lead sponsor	Vanderbilt University
Phase	Phase 1
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	single
Primary purpose	basic science
Enrollment	2
Start date	1 April 2016
Primary completion	1 December 2026
Estimated completion	1 December 2026
Sites	1 location across United States

Drugs / interventions tested

Trimethaphan — full drug profile →
Placebo

Conditions studied

Multiple System Atrophy — all drugs for Multiple System Atrophy →
Orthostatic Hypotension — all drugs for Orthostatic Hypotension →
Supine Hypertension — all drugs for Supine Hypertension →

Sponsor

Vanderbilt University

Who can join

Adults 40 to 80, any sex, with Multiple System Atrophy or Orthostatic Hypotension. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

The percentage of increase of the y intercept of the P-V relationship
Time frame: 5 years
To determine whether autonomic blockade with trimethaphan increases splanchnic capacitance (parallel upward shift in the P-V relationship) compared to placebo.

Sponsor's own description

The purpose of this study is to learn more about the regulation of the veins of the abdomen by the autonomic (involuntary) nervous system, and how this may affect high blood pressure. Normally, the autonomic nervous system controls how much blood flows in the veins. In people with high blood pressure, however, the autonomic nervous system is changed. This change may affect the way blood flows in the veins of the abdomen which may play a role in their high blood pressure. About 32 participants will be screened for the study. The investigators estimate 16 will be eligible to participate in all of the study days.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Trimethaphan

Trials testing the same drug.

NCT03028571 — Autonomic Blockade and Endogenous Glucose Production · Phase 1 · withdrawn

Other recruiting trials for Multiple System Atrophy

Currently open trials in the same condition.

NCT07197866 — An Extension Trial to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy · Phase 2 · recruiting
NCT06868628 — A Phase 2a Study of Foralumab Nasal in Patients With Multiple System Atrophy (MSA) · Phase 2 · recruiting
NCT07353463 — Shanghai Clinical Cohort - Parkinson's Disease (Reserve) · recruiting
NCT06848231 — A Phase 2 Study of YA-101 in Patients With Multiple System Atrophy · Phase 2 · recruiting
NCT06683365 — Autologous suraL nervE Grafting to the Substantia nigrA in Patients With Synuclienopathies · Phase 1 · recruiting

Other Vanderbilt University trials

Trials by the same sponsor.

NCT06598579 — Evaluation of MBCT Implemented in Vietnamese Buddhist Pagoda · NA · not yet recruiting
NCT06482944 — Whole Food for Families: A Pilot RCT of a Dietary Guidelines-Based Intervention to Prevent Type 2 Diabetes · NA · recruiting
NCT07220746 — Understanding Cognitive-Academic Bidirectionality in Math Learning Disabilities · NA · recruiting
NCT06464497 — Whole Foods for Teens: A Pilot Dietary Intervention to Reduce Body Adiposity in Adolescents With Obesity · NA · recruiting
NCT05472961 — Eye Movements in Visual Search · NA · withdrawn

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02726711 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Vanderbilt University
Last refreshed: 11 March 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02726711.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing